Showing results (81-90 of 329) with videos related to
Sort By:
Pageof 33
JAMA|April 1, 2014
Proportion of US adults potentially affected by the 2014 hypertension guidelineAnn Marie Navar-Boggan, Michael J Pencina, Ken Williams, et al.Circulation|October 29, 2003
Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS)Ken Williams, Allan D Sniderman, Naveed Sattar, et al.Journal of Clinical Lipidology|August 12, 2014
Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trialsAllan D Sniderman, James A Sloand, Philip K T Li, et al.Clinical Chemistry and Laboratory Medicine|December 4, 2004
The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary riskGöran Walldius, Ingmar Jungner, Are H Aastveit, et al.The Lancet. Healthy Longevity|September 13, 2022
An adverse lipoprotein phenotype-hypertriglyceridaemic hyperapolipoprotein B-and the long-term risk of type 2 diabetes: a prospective, longitudinal, observational cohort studyKarol M Pencina, Michael J Pencina, Line Dufresne, et al.The Journal of Biological Chemistry|January 24, 2003
The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating proteinDavid Kalant, Stuart A Cain, Magdalena Maslowska, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|October 22, 2016
Estimating the Population Impact of Lp(a) Lowering on the Incidence of Myocardial Infarction and Aortic Stenosis-Brief ReportMehdi Afshar, Pia R Kamstrup, Ken Williams, et al.JAMA|April 8, 2026
Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering TherapySamuel Luebbe, Allan D Sniderman, Andrew E Moran, et al.European Heart Journal|May 3, 2024
Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular preventionAllan D Sniderman, Line Dufresne, Karol M Pencina, et al.Expert Review of Cardiovascular Therapy|April 2, 2011
Lipid-lowering effects of ezetimibe and simvastatin in combinationNkechinyere Ijioma, Jennifer G RobinsonPageof 33